When an estimated one in eight American adults—surpassing 30 million individuals—reported taking GLP-1 medications such as Ozempic in 2024, according to data compiled by the Kaiser Family Foundation, the implications rippled far beyond the pharmaceutical sector. This seismic shift, originating from treatments for Type 2 diabetes and expanding dramatically into weight management, has captured the attention of investors across the food, supplement, and broader healthcare industries. What was once a niche therapeutic intervention is now fundamentally reshaping market dynamics, forging new categories, and presenting unprecedented investment opportunities within what is being termed the "Economy of Transformation."
The Genesis and Evolution of GLP-1s
The journey of Glucagon-like peptide-1 (GLP-1) receptor agonists from specialized diabetes medication to a widely recognized weight-loss tool has been remarkably swift. Initially approved in the late 2000s for managing blood sugar levels in individuals with Type 2 diabetes, these drugs mimic the action of the natural GLP-1 hormone, which is released after eating. This mimicry leads to several beneficial effects: it stimulates insulin secretion, suppresses glucagon release (thereby lowering blood glucose), slows gastric emptying, and crucially for its burgeoning popularity, promotes satiety, leading to reduced food intake and subsequent weight loss.
Semaglutide, marketed as Ozempic for diabetes and Wegovy for weight management, and tirzepatide, sold as Mounjaro for diabetes and Zepbound for weight loss, have become household names. Their efficacy in achieving significant and sustained weight loss has led to widespread off-label use and a surge in demand that has outpaced supply at times. This has propelled the GLP-1 market into a multi-billion dollar industry, with projections indicating continued exponential growth in the coming years. This widespread adoption, driven by both medical necessity and a desire for improved metabolic health and body composition, is the bedrock upon which the "Economy of Transformation" is being built.
The "Economy of Transformation": A New Paradigm
Brian Sugar, co-founder and managing partner of the San Francisco-based venture capital firm Sugar Capital, has coined the term "Economy of Transformation" to describe the profound market shifts driven by the widespread adoption of GLP-1 medications. His personal experience, having successfully lost 40 pounds on Ozempic, has provided him with a unique vantage point to identify the genuine commercial potential.
"Nobody needs to compete with Ozempic. They need to accessorize it," Sugar asserts, highlighting a critical insight into the emerging market. He observes that many pitches he receives, touting products like berberine, metabolic teas, or Akkermansia probiotics as "nature’s Ozempic," fundamentally misunderstand the landscape. These approaches, he contends, are attempting to replicate or replace the drug itself, rather than addressing the complex, and often permanent, physiological changes it induces.
Sugar identifies several common side effects and physiological alterations associated with GLP-1 medications, including potential muscle loss, compromised protein absorption, depletion of essential minerals like magnesium, and hair thinning. "These aren’t problems to solve so you can return to normal," he explains. "Normal is gone. These are the permanent conditions of transformation." This perspective shifts the focus from a temporary diet solution to a sustained, altered metabolic state that requires ongoing support and adaptation.
This understanding has guided Sugar Capital’s investment strategy. Their participation in Grüns, a celebrity-backed brand offering gummies formulated with 60 ingredients, including whole foods, adaptogens, and prebiotics, exemplifies this approach. Sugar Capital invested in Grüns’ $1.8 million pre-seed round in 2023 and its subsequent $35 million Series B round this year. The brand’s objective is to address critical nutrient deficiencies that arise when individuals consume significantly less food. "Bodies consuming 40% fewer calories still need complete nutrition," Sugar states. "They aren’t selling to people on diets. They’re selling to people in different bodies." This strategic positioning targets the long-term nutritional needs of individuals undergoing metabolic transformation, rather than offering a quick fix.
Emerging Investment Categories
The significant market penetration of GLP-1s has spurred the development of distinct investment categories, as various entities seek to cater to this expanding demographic. Investors are identifying and capitalizing on the unique needs and challenges presented by this population.
1. Nutrition Support Platforms: Bridging the Gap with Professional Guidance
The venture capital market is responding with substantial funding for platforms that connect individuals with registered dietitians and nutritionists. These services aim to provide personalized dietary guidance, essential for navigating the nutritional complexities of GLP-1 therapy.
Berry Street, a company offering "nutrition therapy, covered by insurance," secured $50 million in funding earlier this year from investors including Northzone, Sofina, and FJ Labs. Similarly, Fay Nutrition, an AI-powered "preventative care platform" that also pairs users with licensed nutrition professionals, announced in October a $50 million Series B funding round from prominent investors such as Goldman Sachs, General Catalyst, and Forerunner Ventures.
Noah Kotlove, CEO of Berry Street, co-founded the company in 2023 after his own positive experience with a nutritionist who helped him lose 65 pounds. He recognized a significant gap: while most insurance companies cover nutrition consultations, awareness and utilization of these services were surprisingly low. Berry Street’s platform simplifies the process of finding, connecting with, and paying for these essential services. "Insurance companies are happy to pay for [nutrition consultations] because it’s preventing more costly treatment," Kotlove explains. "GLP-1s have hastened this prioritization as they’re becoming such an unwieldy cost for insurers." The increasing burden of managing chronic conditions, including obesity and diabetes, makes preventative measures like nutritional counseling a financially prudent investment for insurers.
Michele Rager, Berry Street’s head of clinical nutrition, reports that over 20% of their platform’s patients are currently using GLP-1s and are engaged in daily consultations with registered dietitians. Rager has witnessed the evolution of GLP-1s firsthand over the past five years, moving from their initial use for Type 2 diabetes to their popularization for weight loss by celebrities and subsequent widespread prescription for weight management. "GLP-1s are now something I hear and talk about from a higher leadership level every day," she notes.
Rager emphasizes that GLP-1s should not be considered a "magic bullet." Instead, their efficacy is maximized when combined with comprehensive lifestyle and behavioral changes, including dietary adjustments and, often, the strategic use of vitamins and supplements. While some nutritional supplements may offer modest, statistically significant benefits, Rager asserts that the most impactful changes, beyond the prescribed medications, stem from fundamental lifestyle modifications: "the lion’s share of impact you can make, other than with these prescribed medications, is with lifestyle and diet, making sure you’re eating the right things, moving properly and supporting all these healthy lifestyle factors."
2. The Healthier Food Push: Nutrient Density and "Food as Medicine"
The GLP-1 trend is also catalyzing a broader movement towards healthier food options and the concept of "food as medicine" (FAM). Marcia Hooper, a partner at Branch Venture Group, an angel investment network focused on food and beverage CPG, foodtech, and agtech ventures, notes that while her group hasn’t yet invested directly in GLP-1-specific companies, they are closely monitoring the space due to its alignment with their "food as medicine" focus.
FAM programs, which encompass initiatives like medically tailored meals and produce prescriptions, aim to provide nutritious, food-insecure individuals with access to healthy food. These programs have historically been led by charitable organizations and publicly funded health insurance initiatives. However, there is a growing trend of private insurers piloting FAM programs for eligible patients, recognizing the therapeutic potential of food in managing chronic conditions.
Hooper highlights the critical nutritional implications for individuals on GLP-1s: "But you lose a lot of muscle mass and bone density. Since most people feel like eating less," she observes, "what they consume needs to be nutrient dense to keep muscle tissue vibrant." This necessitates a reevaluation of dietary intake, prioritizing foods that offer maximum nutritional value with minimal volume.
These nutritional ripple effects are creating fertile ground for new product development. Larissa Zimberoff, author of "Technically Food: Inside Silicon Valley’s Mission to Change What We Eat," indicates that major food companies are keenly observing the GLP-1 trend. She connects this trend to a growing consumer sentiment against ultra-processed foods (UPFs). "Consumers on GLP-1s are buying less junk food but still snacking. They’re looking for healthier options," Zimberoff states. "Because they’re eating far less, getting the right nutrients in the right amounts becomes critical." This shift suggests a demand for products that are not only less processed but also more nutritionally concentrated.
Both Hooper and Zimberoff point to several ways corporate food companies are responding to the GLP-1 trend, including:
- Reformulating existing products: Companies are exploring ways to enhance the nutritional profile of their offerings, increasing protein, fiber, and essential micronutrients while reducing added sugars and unhealthy fats.
- Developing new product lines: The emergence of specialized food products designed to meet the specific nutritional needs of individuals on GLP-1s is anticipated. This could include nutrient-dense snack bars, high-protein beverages, and meal replacements optimized for satiety and micronutrient delivery.
- Investing in food technology: Companies are likely to invest in innovative food technologies that can create more nutrient-dense and palatable food options, potentially leveraging advancements in ingredient science and processing techniques.
3. Specialized Supplement Development: Addressing Specific Needs
Beyond broad nutritional support, there is a significant "big opening" for vitamin and supplement manufacturers to develop specialized products tailored to the unique physiological changes associated with GLP-1 use. Zimberoff cites GNC’s creation of dedicated GLP-1 supplement sections as a prime example. These sections feature products designed to:
- Support GLP-1 production and metabolic health: Some supplements aim to bolster the body’s natural GLP-1 pathways or support overall metabolic function.
- Enhance nutrient absorption: With potential issues like protein malabsorption, supplements focusing on digestive enzymes, probiotics, and prebiotics are gaining traction to optimize nutrient uptake.
- Provide high-protein formulations: To combat muscle loss and ensure adequate protein intake within a reduced caloric budget, high-protein supplements with minimal volume are becoming essential. This includes powders, shakes, and ready-to-drink options.
- Support muscle growth and recovery: For individuals focused on maintaining or building muscle mass, specialized sports nutrition products are being developed.
Zimberoff also points to the development of fiber and prebiotic products to address digestive changes commonly experienced by GLP-1 users. Inflammation is identified as another area of potential growth within the GLP-1 consumer base, suggesting a demand for anti-inflammatory supplements and ingredients.
4. Foodtech Innovation Pipeline: Concentrated Nutrition for Evolving Palates
The demand for better-for-you products, driven by both the broader consumer market and specifically by the GLP-1 trend, is prompting ingredient companies and food technologists to innovate. Mista, a San Francisco-based food laboratory backed by investors such as Givaudan and Ingredion, exemplifies this innovation pipeline.
Scott May, co-founder and chief of Mista, explains the company’s role: "is to identify and curate early-stage companies that are bringing unique, interesting technologies to the forefront and disrupting many parts of the food system. We help connect these start-ups to big companies, so they can begin to incorporate them into portfolios." The overarching objective is to "highlight the potential of combining new ingredient technologies with existing solutions."
At Mista’s Healthy Nutrition Symposium in March, representatives from 60 companies convened to address challenges posed by the GLP-1 and UPF trends. One working group was tasked with creating a product for GLP-1 users experiencing reduced appetite and struggling to meet their protein and nutrient requirements. The resulting prototype was a 125-milliliter beverage containing 21 grams of protein and 5 grams of fiber, fortified with encapsulated vitamins A, D, and E to provide 100% of the daily value, all without the characteristic "vitamin taste."
This demonstration product, with its concentrated nutrition delivered in a minimal volume format reminiscent of energy shots, represents the type of innovative solution the GLP-1 market is actively seeking. It addresses the dual challenges of reduced food intake and the critical need for dense, bioavailable nutrition.
Investment Implications: A Long-Term Perspective
Marcia Hooper offers a compelling analogy for understanding the impact of GLP-1s: "I think of GLP-1s like eyeglasses for the gut. If you’re nearsighted or farsighted, corrective lenses really help you. And if your gut doesn’t digest food at a speed that can work with your metabolism, a GLP-1 can be really helpful." This perspective underscores that GLP-1 medications are increasingly viewed not as a temporary diet aid but as a permanent tool for metabolic health management.
This permanence transforms the market landscape, creating sustainable opportunities for investors who look beyond traditional weight-loss categories and embrace a more holistic view of health and wellness. The GLP-1 trend presents a multi-tiered investment horizon:
- Immediate Opportunities: These lie in nutritional support services, particularly those with established insurance reimbursement models, such as telehealth platforms connecting patients with dietitians and nutritionists.
- Medium-Term Opportunities: These involve the development of specialized supplements specifically formulated to address GLP-1-induced side effects and nutritional gaps, such as protein deficiencies, mineral depletion, and digestive health concerns.
- Longer-Term Opportunities: These encompass the realm of food technology innovation, focusing on the creation of nutrient-dense, minimal-volume food and beverage products that cater to the evolving dietary needs and preferences of individuals undergoing metabolic transformation.
The supplement industry, in particular, is at a critical juncture. A fundamental shift is underway, moving from serving individuals primarily focused on weight loss to supporting those living with permanently transformed metabolisms. Companies that can adapt their product development, marketing, and business strategies to this new reality are poised for significant growth in the burgeoning "Economy of Transformation." The sustained impact of GLP-1s signifies not just a medical breakthrough, but a profound societal and economic evolution that will continue to shape the future of health, nutrition, and investment for years to come.